关键信息
-
基因名
GLRA3
- 应用
-
别名
GLRA 3; Glra3; GLRA3_HUMAN; Glycine receptor alpha 3 polypeptide; Glycine receptor alpha 3 subunit; Glycine receptor subunit alpha 3; Glycine receptor subunit alpha-3; Ligand gated ion channel
-
种属
Human
-
表达系统
E. coli
-
标签
GST-tag at N-terminal
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
O75311
-
表达区间
34-464aa
-
氨基酸序列
ARSRSAPMSPSDFLDKLMGRTSGYDARIRPNFKGPPVNVTCNIFINSFGSIAETTMDYRVNIFLRQKWNDPRLAYSEYPDDSLDLDPSMLDSIWKPDLFFANEKGANFHEVTTDNKLLRIFKNGNVLYSIRLTLTLSCPMDLKNFPMDVQTCIMQLESFGYTMNDLIFEWQDEAPVQVAEGLTLPQFLLKEEKDLRYCTKHYNTGKFTCIEVRFHLERQMGYYLIQMYIPSLLIVILSWVSFWINMDAAPARVALGITTVLTMTTQSSGSRASLPKVSYVKAIDIWMAVCLLFVFSALLEYAAVNFVSRQHKELLRFRRKRKNKTEAFALEKFYRFSDMDDEVRESRFSFTAYGMGPCLQAKDGMTPKGPNHPVQVMPKSPDEMRKVFIDRAKKIDTISRACFPLAFLIFNIFYWVIYKILRHEDIHQQQD
-
分子量
73.15 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
GLRA3, or Glycine Receptor Alpha Subunit 3, is a member of the ionotropic glycine receptor family, which plays a crucial role in inhibitory neurotransmission within the central nervous system. It primarily mediates synaptic inhibition by allowing chloride ions to flow into neurons upon binding glycine, thus calming excessive neuronal activity. Mutations or dysregulation of GLRA3 have been implicated in various neurological disorders, including certain forms of epilepsy, schizophrenia, and movement disorders. Research into the recombinant expression of GLRA3 protein is vital for understanding its functional properties, interaction with ligands, and the mechanisms underlying its involvement in these pathological conditions. The ability to produce and purify GLRA3 in a laboratory setting facilitates structural and biophysical studies, which are essential for developing therapeutic strategies aimed at modulating glycinergic signaling. Furthermore, advances in recombinant technology have opened avenues for exploring the receptor's pharmacological profiles and identification of potential drug targets, thus paving the way for novel treatments for related neurophysiological disorders. The investigation of GLRA3 not only contributes to our understanding of glycinergic neurotransmission but also highlights its significance in neuropharmacology and potential clinical applications.
